Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

LeMaitre Vascular (NASDAQ:LMAT - Get Rating) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Friday.LeMaitre Vascular Stock Up 1.0 %

NASDAQ:LMAT opened at $50.74 on Friday. The stock has a market cap of $1.11 billion, a P/E ratio of 50.24, a price-to-earnings-growth ratio of 4.21 and a beta of 1.19. The firm's fifty day simple moving average is $49.83 and its 200 day simple moving average is $46.63. LeMaitre Vascular has a twelve month low of $38.32 and a twelve month high of $60.21. Insider Activity at LeMaitre Vascular

In other news, CFO Joseph P. Pellegrino, Jr. sold 18,693 shares of the business's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $53.99, for a total transaction of $1,009,235.07. Following the sale, the chief financial officer now owns 6,108 shares in the company, valued at approximately $329,770.92. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CFO Joseph P. Pellegrino, Jr. sold 18,693 shares of the business's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $53.99, for a total transaction of $1,009,235.07. Following the sale, the chief financial officer now owns 6,108 shares in the company, valued at approximately $329,770.92. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO George W. Lemaitre sold 17,702 shares of the business's stock in a transaction on Monday, August 15th. The shares were sold at an average price of $55.89, for a total transaction of $989,364.78. Following the sale, the chief executive officer now owns 2,507,476 shares in the company, valued at approximately $140,142,833.64. The disclosure for this sale can be found here. Insiders have sold a total of 64,633 shares of company stock worth $3,534,996 over the last quarter. Corporate insiders own 12.50% of the company's stock. Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds have recently bought and sold shares of the company. Captrust Financial Advisors boosted its stake in LeMaitre Vascular by 555.3% in the 1st quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 522 shares in the last quarter. FinTrust Capital Advisors LLC bought a new position in LeMaitre Vascular in the 2nd quarter worth about $76,000. Hardy Reed LLC bought a new position in LeMaitre Vascular in the 1st quarter worth about $91,000. Lazard Asset Management LLC boosted its stake in LeMaitre Vascular by 48.8% in the 2nd quarter. Lazard Asset Management LLC now owns 2,563 shares of the medical instruments supplier's stock worth $116,000 after purchasing an additional 841 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in LeMaitre Vascular by 2,150.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,678 shares of the medical instruments supplier's stock worth $122,000 after purchasing an additional 2,559 shares in the last quarter. Institutional investors own 88.45% of the company's stock. LeMaitre Vascular Company Profile (Get Rating)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.Featured ArticlesGet a free copy of the StockNews.com research report on LeMaitre Vascular (LMAT)Oil and Gas Stocks: A Safe Way to Invest in Renewable EnergyAre These Green Energy Companies Right For Your Portfolio?When Will the Hangover Finally Be Over for Seagate Technology?Does Enphase Energy Have the Juice to Keep Powering Higher? The One Hydrogen Fuel Cell Stock To Rule Them All 

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider LeMaitre Vascular, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.

While LeMaitre Vascular currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Michael Wang of Prometheus Alternative Investments discusses how individuals should approach their portfolios as the summer rally seems to have fizzled.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.